08:00 , Dec 11, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Bone repair N-terminal acetyltransferase complex ARD1 subunit homolog A (NAA10; ARD1A; ARD1); runt-related transcription factor 2 ...
07:00 , Jul 22, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer N-Terminal acetyltransferase complex ARD1 subunit homolog A (NAA10; ARD1A; ARD1); DNA (cytosine-5-)-methyltransferase 1 (DNMT1) In vitro,...
07:00 , Jul 22, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) NK cells Studies in patient-derived cells and in mice suggest that depleting NK...
07:00 , Mar 18, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer N(a)-acetyltransferase 10 (NAA10; ARD1A) In vitro and mouse studies suggest that increasing ARD1A expression...